SLC19A1: A Protein Potential Drug Target Or Biomarker (G6573)

Target Name: SLC19A1

NCBI ID: G6573

SLC19A1

SLC19A1: A Protein Potential Drug Target Or Biomarker

SLC19A1 (Solute carrier family 19 member 1, transcript variant 4) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the SLC19 family, which is known for its role in transporting small molecules across cell membranes. SLC19A1 is the gene encoding the protein, and its function is not well understood.

One possible function of SLC19A1 is as a drug target or biomarker. Many diseases, including neurodegenerative disorders, are characterized by the buildup of toxic substances in the brain, which can cause damage to the nervous system and lead to a range of symptoms. Drugs that can selectively target SLC19A1 and block its function may be useful in treating these diseases. For example, SLC19A1 has been shown to be involved in the transport of certain classes of drugs, including many neurotransmitters that are involved in mood, anxiety, and other neurological disorders. By inhibiting SLC19A1 function, these drugs may be able to reduce the amount of these substances in the brain and improve symptoms.

SLC19A1 is also a potential biomarker for some neurological disorders. The buildup of toxic substances in the brain can cause a range of changes in the expression of genes, including changes in the levels of SLC19A1. By detecting these changes in SLC19A1 expression, researchers may be able to develop biomarkers that can be used to diagnose and monitor certain neurological disorders. For example, SLC19A1 levels have been shown to be elevated in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder that is characterized by the buildup of toxic substances in the brain. By detecting these changes in SLC19A1 expression, researchers may be able to develop diagnostic tests for Alzheimer's disease.

In addition to its potential as a drug target or biomarker, SLC19A1 is also of interest because of its location in the body. The brain is a complex organ that is responsible for controlling and coordinating all of the body's functions, and it is surrounded by a large number of blood vessels and other tissues. The blood vessels in the brain are essential for delivering oxygen and nutrients to the brain, and they are also the sites of many neurotransmitter transports, including the transport of drugs. By targeting SLC19A1, drugs may be able to reduce the amount of these substances in the brain and improve the effectiveness of these treatments.

Overall, SLC19A1 is a protein that is expressed in various tissues of the body and is involved in the transport of small molecules across cell membranes. Its function is not well understood, but it is potential as a drug target or biomarker for a range of neurological disorders. Further research is needed to fully understand the role of SLC19A1 in the body and to develop effective treatments based on its properties.

Protein Name: Solute Carrier Family 19 Member 1

Functions: Antiporter that mediates the import of reduced folates or a subset of cyclic dinucleotides, driven by the export of organic anions (PubMed:7826387, PubMed:9041240, PubMed:10787414, PubMed:15337749, PubMed:16115875, PubMed:22554803, PubMed:31511694, PubMed:31126740, PubMed:32276275). Mechanistically, acts as a secondary active transporter, which exports intracellular organic anions down their concentration gradients to facilitate the uptake of its substrates (PubMed:22554803, PubMed:31511694, PubMed:31126740). Has high affinity for N5-methyltetrahydrofolate, the predominant circulating form of folate (PubMed:10787414, PubMed:14609557, PubMed:22554803). Also able to mediate the import of antifolate drug methotrexate (PubMed:7615551, PubMed:7641195, PubMed:9767079, PubMed:22554803). Also acts as an importer of immunoreactive cyclic dinucleotides, such as cyclic GMP-AMP (2'-3'-cGAMP), an immune messenger produced in response to DNA virus in the cytosol, and its linkage isomer 3'-3'-cGAMP, thus playing a role in triggering larger immune responses (PubMed:31511694, PubMed:31126740). 5-amino-4-imidazolecarboxamide riboside (AICAR), when phosphorylated to AICAR monophosphate, can serve as an organic anion for antiporter activity (PubMed:22554803)

The "SLC19A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC19A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets